Pittsburgh, USA | May 1, 2026
Viatris has announced multiple clinical data presentations for its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting, highlighting positive Phase 3 efficacy, safety, and pharmacokinetic outcomes. The investigational transdermal patch represents a next-generation contraceptive solution designed to deliver effective pregnancy prevention with lower estrogen exposure and improved patient convenience through once-weekly dosing.
Phase 3 Data Demonstrates Efficacy and Safety
The presentations include results from a multicenter Phase 3 clinical study (NCT05139121) evaluating the contraceptive efficacy and safety of the investigational weekly patch in women of childbearing potential. The study demonstrated a favorable efficacy profile, confirming reliable pregnancy prevention alongside a strong safety profile, supporting its potential as a viable alternative to traditional oral contraceptives. In addition, cycle control data and safety insights further validate the patch’s clinical performance, reinforcing its suitability for long-term use. These findings highlight the continued evolution of hormonal contraceptive therapies toward improved tolerability and patient-centered design.
Advanced Transdermal Delivery and Adhesion Performance
A key focus of the data presentations is the patch’s adhesion performance under both normal and extreme conditions, as well as its pharmacokinetic profile compared to oral contraceptive formulations. The investigational patch demonstrated consistent adhesion and drug delivery performance, ensuring reliable hormone release throughout the weekly dosing period.
Advertisement
Pharmacokinetic analyses showed comparable systemic exposure to established oral contraceptives, confirming its effectiveness as a transdermal alternative. This innovation builds on Viatris’ expertise in drug delivery technologies, offering a non-invasive, reversible contraceptive option with improved compliance potential.
Regulatory Progress and NDA Review Pathway
The investigational patch is currently under U.S. Food and Drug Administration (FDA) review, with a New Drug Application (NDA) accepted under the 505(b)(2) pathway and a target action date of July 30, 2026. This regulatory milestone underscores the robustness of the clinical data package and the therapy’s readiness for potential market approval, pending final review. The product is specifically designed for women seeking a lower-dose estrogen contraceptive option, addressing safety concerns associated with higher estrogen exposure while maintaining contraceptive efficacy.
Addressing Unmet Needs in Women’s Health
The development of this low-dose estrogen weekly patch reflects a broader shift toward personalized and patient-friendly contraceptive solutions, particularly for individuals seeking alternatives to daily oral regimens. By combining reduced estrogen exposure with convenient weekly dosing and strong adhesion performance, the therapy aims to improve adherence, reduce side effects, and enhance overall patient experience. The product also builds upon existing transdermal contraceptive technologies, representing a lifecycle innovation that advances current standards of care in reproductive health.
Source: Viatris press release
